V3003
Monoclonal Anti-Vascular Endothelial Growth Factor Receptor-2 (KDR) antibody produced in mouse
clone 260.4, KDR-2, ascites fluid
Synonym(s):
Monoclonal Anti-Vascular Endothelial Growth Factor Receptor-2 antibody produced in mouse, Anti-KDR, Anti-VEGFR-2
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
51111800
NACRES:
NA.41
Recommended Products
biological source
mouse
conjugate
unconjugated
antibody form
ascites fluid
antibody product type
primary antibodies
clone
260.4, KDR-2, monoclonal
contains
15 mM sodium azide
species reactivity
human
technique(s)
immunohistochemistry (frozen sections): suitable
indirect ELISA: suitable
western blot: 1:500 using insect cell culture supernatant expressing human extracellular recombinant VEGFR or VEGF Receptor-2 (KDR, FLK-1)/FC Chimera human, recombinant
isotype
IgG1
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... KDR(3791)
Looking for similar products? Visit Product Comparison Guide
General description
Monoclonal Anti-Vascular Endothelial Growth Factor Receptor-2 (mouse IgG1 isotype) is derived from the KDR-2 hybridoma produced by the fusion of mouse myeloma cells and splenocytes from an immunized mouse. Vascular endothelial growth factor receptor 2 (VEGFR2) is a type V receptor tyrosine kinase, also known as kinase insert domain receptor (KDR) or fetal liver kinase 1 (Flk-1). It a glycosylated protein with an immunoglobulin (Ig)-like domains, a transmembrane domain and a tyrosine kinase domain. The KDR gene is mapped to human chromosome 4q12 and is widely expressed in all vessel-derived endothelial cells and hematopoietic stem cells.
Specificity
Reacts specifically with human VEGF receptor-2. This clone has also been termed 260.4. It does not recognize Flt1 (VEGFR-1), Flt4 (VEGFR-3), or platelet-derived growth factor receptor (PDGF-R).
Immunogen
purified recombinant human extracellular VEGF receptor-2 (KDR).
Application
Monoclonal Anti-Vascular Endothelial Growth Factor Receptor-2 (KDR) antibody produced in mouse has been used in:
- immunofluorescence
- immunohistochemistry
- immunoblotting
- enzyme-linked immunosorbent assay(ELISA)
Biochem/physiol Actions
Vascular Endothelial Growth Factor Receptor-2 (VEGF R2) have high affinity for vascular endothelial growth factor-A (VEGF-A), hence facilitates most of the endothelial growth and survival signals from VEGF-A. It also plays a pivotal role in vascular development, vascular permeability, embryonic hematopoiesis and regulation of angiogenesis.
Vascular endothelial growth factor receptor 2 (VEGFR2) or kinase insert domain receptor (KDR) is a VEGF receptor, which stimulates its mitogenic activity. It is crucial for vascular endothelial cell development. VEGFR2 expression is elevated in invasive breast cancer, hemangiomas and angiosarcomas. KDR expressing cells show striking changes in cell morphology, actin reorganization and membrane ruffling, chemotaxis, and mitogenicity in response to VEGF. Antibodies that react specifically with the VEGF receptor are useful for the study of the specific differential tissue expression and intracellular localization of the receptor in normal and neoplastic tissue.
Target description
The KDR receptor (VEGFRa), defining marker of hematopoietic stem cells (HSCs), distinguishes pluripotent HSCs from lineage-committed progenitor HSCs.
Physical form
The product is provided as ascites fluid with 15 mM sodium azide as a preservative.
Storage and Stability
For continuous use, store at 2-8 °C for up to one month. For extended storage freeze in working aliquots. Repeated freezing and thawing, or storage in "frost-free" freezers,is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
10 - Combustible liquids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Irawan Satriotomo et al.
Experimental neurology, 237(1), 103-115 (2012-06-19)
Acute intermittent hypoxia (AIH) initiates plasticity in respiratory motor control, including phrenic long term facilitation (pLTF). Since pLTF is enhanced by preconditioning with repetitive exposure to AIH (rAIH), we hypothesized that a rAIH protocol consisting of 3 AIH exposures per
S Ogawa et al.
The Journal of biological chemistry, 273(47), 31273-31282 (1998-11-13)
Vascular endothelial growth factor (VEGF) mediates endothelial cell proliferation, angiogenesis, and vascular permeability via the endothelial cell receptors, KDR/Flk-1 and Flt-1. Recently, a gene encoding a polypeptide with about 25% amino acid identity to mammalian VEGF was identified in the
Masabumi Shibuya
Cancer science, 94(9), 751-756 (2003-09-12)
Vascular endothelial growth factor receptor-2 (VEGFR-2/KDR/Flk-1) is a high-affinity receptor for vascular endothelial growth factor-A (VEGF-A), and mediates most of the endothelial growth and survival signals from VEGF-A. VEGFR-2 has a typical tyrosine kinase receptor structure with seven immunoglobulin (Ig)-like
J M Ou et al.
European journal of histochemistry : EJH, 58(1), 2263-2263 (2014-04-08)
Angiogenesis is a process of development and growth of new capillary blood vessels from pre-existing vessels. Angiogenic growth factors play important roles in the development and maintenance of some malignancies, of which vascular endothelial growth factor (VEGF)/VEGFR2 interactions are involved
I Satriotomo et al.
Neuroscience, 322, 479-488 (2016-03-06)
Repetitive acute intermittent hypoxia (rAIH) increases growth/trophic factor expression in respiratory motor neurons, thereby eliciting spinal respiratory motor plasticity and/or neuroprotection. Here we demonstrate that rAIH effects are not unique to respiratory motor neurons, but are also expressed in non-respiratory
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service